Alzheimer’s disease

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular plaques of amyloid-β (Aβ) and intracellular networks of neurofibrils. This disease is the most common and debilitating cause of dementia in the elderly population. It affects 50 million people worldwide and is steadily increasing in many countries due to increasing life expectancy. There is currently no treatment for this disease

Nanolithium (NP03) for the tratment of Alzheimer Disease

Preclinical studies were carried out on an animal model of the disease (McGill-R-Thy1-APP Alzheimer transgenic rat) to evaluate the therapeutic effect of NP03 as a disease-modifying treatment, in collaboration with Claudio Cuello’s team (McGill University, Montreal, Canada). Claudio Cuello is internationally known for his work on this disease and has developed this animal model.

Wilson EN, Do Carmo S, Welikovitch LA, Hall H, Aguilar LF, Foret MK, Iulita F, Jia DT, Marks AR, Allard S, Emmerson JT, Ducatenzeiler A, and Cuello C – NP03, a microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats – J. of Alzheimer’s Disease, 73 (2020) 723-739.

Wilson EN, Do Carmo S, Iulita MF, Hall H, Austin G, Jia D, Malcolm J, Foret M, Marks AR, Butterfield D and Cuello C, – Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat model of Alzheimer’s-like Amyloidosis – Current Alzheimer Research, 2018, 15, 1220-1230

Wilson EN, Do Carmo S, Iulita MF, Hall H, Ducatenzeiler A, Marks AR, Allard S, Jia DT, Windheim J and Cuello A; BACE 1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology – Translational Psychiatry (2017) 7, e1190.

The results were as follows:
NP03 corrects or delays deficits in various cognitive and/or behavioral tests, strongly decreases the expression of the Aβ peptide and the expression of BACE1, inhibits GSK-3β, and it induces neurogenesis in the seahorse.
A phase I trial has been completed.

A phase II study will start in the first semester of 2022

in six university hospital centers in France (Toulouse, Montpellier, Marseille, Lyon, Lille and Paris)